Evotec SE announced it has received a payment of US$ 25 million from Bristol Myers Squibb in recognition of scientific progress achieved within their long-term neuroscience partnership. The milestone will support further research and advance their joint pipeline targeting neurodegenerative diseases.
Established in 2016, the collaboration focuses on developing disease-modifying therapies for neurodegenerative disorders, where current treatment options remain inadequate. Over the years, the partnership has delivered a robust pipeline of innovative candidates, including EVT8683—licensed by Bristol Myers Squibb in 2021 as BMS-986419—which has successfully completed Phase 1 clinical trials. In 2023, the companies extended their collaboration for an additional eight years, underscoring their shared commitment to advancing transformative treatments.Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, stated: “Patients living with neurodegenerative conditions urgently need therapies that go beyond the management of symptoms. This achievement increases the depth of our collaboration with Bristol Myers Squibb. Together, we are translating emerging disease biology into potential therapeutic opportunities, with the goal of providing meaningful new options for patients suffering from neurodegenerative diseases.”
Evotec is a global life science company pioneering AI-driven, end-to-end drug discovery and development. With expertise spanning small molecules, biologics, and cell therapies, and collaborations with all Top 20 pharma companies, Evotec integrates breakthrough science, proprietary platforms, and global R&D excellence to accelerate the path from concept to cure.